- 博奥信将获得超过4000万美元的现金付款，作为首付款以及承担部分开发成本和药物产品材料费用，同时博奥信还将获得 Aclaris Therapeutics 19.9% ...

▲点击上方的蓝色“医谷”关注我们日前，博奥信生物宣布与Aclaris ...

根据协议条款，博奥信将获得超过4000万美元的现金付款，作为首付款以及承担部分开发成本和药物产品材料费用。博奥信还将获得Aclaris Therapeutics ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Leerink Partners has recently raised Aclaris Therapeutics Inc (ACRS) stock to Outperform rating, as announced on Today, according to Finviz. Earlier, on Today, Jefferies had raised the stock from a ...

周二，Leerink Partners调整了对Aclaris Therapeutics (NASDAQ:ACRS)的立场，将公司股票评级从"市场表现"上调至"跑赢大市"。该公司分析师还大幅提高了Aclaris Therapeutics的目标价，将其从之前的$2.00上调至$7.00。 此次上调是在Aclaris Therapeutics完成战略评估之后进行的，Leerink Partners认为这 ...

智通财经APP获悉，生物制药公司Aclaris Therapeutics (ACRS.US)股价周一上涨53%，至3.14美元，此前该公司宣布获得Biosion独家授权的两种免疫候选药物，这促使Piper Sandler上调了对该公司的评级。

Under the agreement, Biosion will receive over $40 million cash as an upfront license fee and reimbursement for certain development costs and drug product materials. Biosion said it will receive 19.9% ...

当地时间周二，美股三大指数收盘涨跌不一，纳指涨1.04%，标普500指数涨0.4%，道指跌0.28%。纳斯达克生物科技指数收涨0.33%，Aclaris Therapeutics暴涨46.18%领跑指数，阿佩利斯涨超10%，阿斯利康、ILLUMINA ...

Leerink upgraded Aclaris Therapeutics (ACRS) to Outperform from Market Perform with a price target of $7, up from $2, representing over 120% ...

2024年11月18日，博奥信宣布将TSLP抗体BSI-045B、TSLP/IL-4R双抗的大中华区外全球权益授权给Aclaris ...

周二，Jefferies分析师将Aclaris Therapeutics Inc. (NASDAQ:ACRS)的股票评级从"持有"上调至"买入"。分析师还大幅提高了该公司股票的目标价，将其从之前的$2.00上调至$7.00。 此次上调是在分析师与公司管理层讨论了其药物候选BSI-045B后做出的。该药物在特应性皮炎(AD)的临床概念验证(POC)中表现出了前景。 该药物独特的结合特性被认为是其潜在 ...